Barron's
http://online.barrons.com/public/mainBarron's Magazine is a weekly financial newspaper that covers US financial information, market developments, and relevant statistics. Each issue provides a summary of the previous week's market activity, news reports, and an outlook on the week to come. The paper has been published since 1921 by Dow Jones & Company, the publisher of The Wall Street Journal. The paper is named after Clarence W. Barron who is considered the founder of financial journalism.
Wedbush Securities to Host Its Annual PacGrow Healthcare Management Access Conference in August 2015
-
Roche's (RHHBY) Genentech Receives FDA Approval for ACTEMRA as PJIA Treatment
-
Roche's (RHHBY) Genentech Receives Expanded Indication for ACTEMRA
-
Roche (RHHBY) to Stop Dalcetrapib dal-OUTCOMES Phase III Trial
-
Competition, Spending Cuts Make Illumina (ILMN) One Risky Play - Barron's
-
Novartis (NVS) Could Formulate Strong Results in 2012 - Barron's
-
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
-
Roche' (RHHBY) Genentech Gets U.S. FDA Approval for Lengthening Therapy with Valcyte in Kidney Transplant Patients With High-Risk of CMV Disease
-
Roche's (RHHBY) Genentech Announces Positive Data in Avastin Phase III in Women with Ovarian Cancer
-
Roche Group's (RHHBY) Genetech and Biogen Itec (BIIB) Announce Positive Data from Rituxan Phase III
-
Roche (RHHBY) and Biogen Idec (BIIB) Announce Discontinuation of Ocrelizumab Development Program